<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01560143</url>
  </required_header>
  <id_info>
    <org_study_id>11-007</org_study_id>
    <secondary_id>WS2001231</secondary_id>
    <nct_id>NCT01560143</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects</brief_title>
  <official_title>Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Manjunath Prakash Pai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      If tigecycline clearance increases with body size then serum exposure values will be lower in
      obese class III compared to normal weight subjects because exposure changes inversely with
      clearance when the dose is fixed without regard to weight.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Not required
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Single-dose Serum AUC of Tigecycline Between Time 0 and 96 Hours</measure>
    <time_frame>4 days (96 hours)</time_frame>
    <description>The AUC is the area under the concentration time curve in serum measured in the unit of concentration in milligram of tigeycline per liter of plasma multiplied by the time interval in hours (hour*mg/L)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Tigecycline</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects receive a single dose of tigecycline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tigecycline</intervention_name>
    <description>100 mg IV as a single infusion over 30 minutes</description>
    <arm_group_label>Tigecycline</arm_group_label>
    <other_name>Tygacil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects fulfilling the following criteria will be eligible:

          1. males and females, 18 to 50 years of age;

          2. non-smoking or light-smoking (≤ 5 cigarettes per day) volunteers;

          3. Body mass index: 18.50-24.99 kg/m2 (normal weight) or ≥ 40 kg/m2 (obese class III);

          4. female subjects of childbearing potential (self-reported) either surgically
             sterilized, using an effective method of contraception (diaphragm, cervical cap,
             condom) or agree to abstain from sex from time of prestudy screening, during entire
             study period and 1 month following the study period

        Exclusion Criteria:

          1. history of significant hypersensitivity reaction to any components of Tygacil®;

          2. history of significant clinical illness requiring pharmacological management;

          3. history of blood donation in the past eight week period;

          4. abnormal serum electrolyte or complete blood count requiring further clinical work-up;

          5. transaminases (AST or ALT) &gt; 2.5 x upper limit of normal;

          6. subjects with stage 4 or 5 chronic kidney disease;

          7. positive serum pregnancy test (if female);

          8. abnormal electrocardiogram (ECG) as judged by study physician;

          9. unable to tolerate venipuncture and multiple blood draws;

         10. clinically significant abnormal physical examination defined as a physical finding
             requiring further clinical work-up;

         11. unable to independently provide a written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manjunath P Pai, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albany College of Pharmacy</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2012</study_first_submitted>
  <study_first_submitted_qc>March 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2012</study_first_posted>
  <results_first_submitted>October 11, 2016</results_first_submitted>
  <results_first_submitted_qc>October 11, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 6, 2016</results_first_posted>
  <last_update_submitted>December 16, 2016</last_update_submitted>
  <last_update_submitted_qc>December 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Manjunath Prakash Pai</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tigecycline</mesh_term>
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The data have been published as a manuscript J Antimicrob Chemother. 2014 Jan;69(1):190-9.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tigecycline</title>
          <description>All subjects receive a single dose of tigecycline
Tigecycline: 100 mg IV as a single infusion over 30 minutes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tigecycline</title>
          <description>All subjects receive a single dose of tigecycline
Tigecycline: 100 mg IV as a single infusion over 30 minutes</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.5" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.8" lower_limit="20.8" upper_limit="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Single-dose Serum AUC of Tigecycline Between Time 0 and 96 Hours</title>
        <description>The AUC is the area under the concentration time curve in serum measured in the unit of concentration in milligram of tigeycline per liter of plasma multiplied by the time interval in hours (hour*mg/L)</description>
        <time_frame>4 days (96 hours)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Serum AUC of Tigecycline</title>
            <description>All subjects receive a single dose of tigecycline
Tigecycline: 100 mg IV as a single infusion over 30 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Single-dose Serum AUC of Tigecycline Between Time 0 and 96 Hours</title>
          <description>The AUC is the area under the concentration time curve in serum measured in the unit of concentration in milligram of tigeycline per liter of plasma multiplied by the time interval in hours (hour*mg/L)</description>
          <units>hour*mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.64" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tigecycline</title>
          <description>All subjects receive a single dose of tigecycline
Tigecycline: 100 mg IV as a single infusion over 30 minutes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Emesis</sub_title>
                <description>Vomitting</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small study sample size</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Manjunath Pai</name_or_title>
      <organization>University of Michigan</organization>
      <phone>7346473466</phone>
      <email>amitpai@med.umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

